Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Expanding research into biomarkers for RPD differentiation

Philip Tipton, MD, Mayo Clinic, Jacksonville, FL, discusses the main points of investigation that his most recent studies are following into rapidly progressive dementia (RPD). RPDs can cause quicker deterioration than other types of dementia, developing over weeks to months. Creutzfeldt-Jackob disease, a rare and fatal brain disease, is often associated with the cause of RPD. Other causes, such as some atypical forms of Alzheimer’s disease (AD), including frontal variant Alzheimer’s disease (fvAD) and posterior cortical atrophy (PCA), may also lead to RPD. Dr Tipton and colleagues are investigating the possible use of biomarkers in patients with quickly deteriorating cognition to differentiate among the types of RPD depending on the cause. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.